Trillium Therapeutics Inc.
IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY

Abstract:

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRP.alpha.Fc. Specific combinations include SIRP.alpha.Fc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.